A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
constituted powder for oral suspension 4 mg/mL single dose at 32 mg
tablets 32 mg single dose
AUCinf (area under the concentration curve to infinity)
Time frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
Cmax (maximum concentration)
Time frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
AUC last (area under the concentration curve to last time point)
Time frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
Tmax (time at maximum concentration)
Time frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
Half-life
Time frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.